Knight Therapeutics launched TAVALISSE for chronic ITP treatment and began expanding its presence through regional agreements in Latin America.
1 report, 1 independent
Updated May 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Knight Therapeutics launched TAVALISSE for chronic ITP treatment and began expanding its presence through regional agreements in Latin America.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Latin America
region of the Americas where Romance languages are primarily spoken
-
Knight Therapeutics
Canadian pharmaceutical company
Nothing else this week.